Procter & Gamble to Acquire Thorne for $3.8 Billion

Procter & Gamble has agreed to acquire Thorne, a supplement manufacturer long positioned around the healthcare practitioner channel, in a deal valued at $3.8 billion.^1,2

For an industry watching how major consumer packaged goods companies are approaching the supplement category, the price tag is notable on its own, as it represents nearly a sixfold return over the $680 million L Catterton paid to take Thorne private less than 3 years ago.²

"For more than 40 years, Thorne has earned the trust of healthcare practitioners, consumers, and partners by putting science, quality, and the people we serve at the center of every decision," commented Colin Watts, Thorne's CEO. "We believe P&G is the right partner to help us expand our impact while staying true to the values and standards that have always defined Thorne."

What Does This Deal Actually Involve, and When Is It Expected to Close?

The transaction moves Thorne from private equity ownership back into a strategic, publicly traded parent company. L Catterton originally acquired Thorne in a $680 million take-private deal in 2023, after the company had gone public in late 2021 at a valuation of $525 million.³

P&G's acquisition price of $3.8 billion reflects Thorne's growth over that period, with the company's revenue surpassing $500 million in 2025.³ The deal remains subject to customary closing conditions and regulatory approval, with P&G targeting a close later this year.

Why Is Thorne Specifically Attractive to a Company Like P&G?

Thorne has built its brand identity around scientific rigor and the healthcare practitioner channel rather than mass retail, a positioning Nutritional Outlook has covered across multiple prior partnership announcements, including sports nutrition collaborations, athlete endorsements tied to its NSF Certified for Sport product line (including with WNBA star Napheesa Collier), and marketing built around personalization and clinical credibility.

Paul Gama, CEO of P&G Health Care, framed the acquisition as directly complementary to that positioning: "Consumer interest in self-care, prevention, wellness, and personalized health continues to grow, and Thorne strengthens our position in premium wellness with a trusted, science-backed brand that complements our existing portfolio." Thorne joins a health care division at P&G that already includes Metamucil, Align Probiotic, and New Chapter, alongside Oral-B and Vicks.

How Does This Fit Into Broader Consolidation Trends in the Supplement Industry?

P&G's move follows a pattern of major consumer goods companies expanding into the vitamins, minerals, and supplements category through acquisition rather than internal product development. Unilever struck a deal earlier this year to acquire gummy supplement maker Grüns, and other strategics have been reported to be evaluating similar opportunities in the space.

P&G shares rose approximately 1% in trading following the announcement.² The transaction adds to a run of high-profile supplement industry acquisitions in 2026, following Procter & Gamble's broader pattern of building out its Personal Health Care division alongside existing brands such as Vicks and Oral-B.¹

References

1. Thorne enters into definitive agreement to be acquired by Procter & Gamble. Thorne. August 4, 2026. Accessed August 5, 2026. https://www.thorne.com/press-releases/thorne-enters-definitive-agreement-to-be-acquired-by-procter-gamble

2. Weingartner T. P&G to buy supplement company for $3.8B. WVXU. August 4, 2026. Accessed August 5, 2026. https://www.wvxu.org/local-news/2026-08-04/p-g-procter-gamble-buy-thorne-supplement

3. Tolomia C. Procter & Gamble is buying supplement brand Thorne for $3.8 billion. Quartz. August 4, 2026. Accessed August 5, 2026. https://qz.com/procter-gamble-acquiring-thorne-supplements-3-8-billion-080426